KalVista Pharmaceuticals's market cap is currently $525.81M. The company's EPS TTM is $-3.64; its P/E ratio is ―; KalVista Pharmaceuticals is scheduled to report earnings on March 12, 2025, and the estimated EPS forecast is $-0.87. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 24	Jun 23	Jun 22	Jun 21	Jun 20
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 12.69M	$ 12.69M
Gross Profit	$ -86.17M	$ -802.00K	$ -743.00K	$ 12.04M	$ 12.65M
Operating Income	$ -140.44M	$ -110.87M	$ -96.61M	$ -57.92M	$ -40.53M
EBITDA	$ -134.28M	$ -92.11M	$ -81.60M	$ -45.59M	$ -40.02M
Net Income	$ -126.64M	$ -74.85M	$ -68.51M	$ -44.49M	$ -29.12M
Balance Sheet
Cash & Short-Term Investments	$ 210.40M	$ 149.38M	$ 166.20M	$ 248.93M	$ 67.71M
Total Assets	$ 235.40M	$ 183.20M	$ 203.88M	$ 272.01M	$ 92.53M
Total Debt	$ 7.32M	$ 8.23M	$ 8.19M	$ 5.91M	$ 1.65M
Net Debt	$ -24.47M	$ -48.01M	$ -22.54M	$ -44.68M	$ -14.14M
Total Liabilities	$ 28.82M	$ 22.18M	$ 18.79M	$ 14.82M	$ 8.78M
Stockholders' Equity	$ 206.58M	$ 161.03M	$ 185.09M	$ 257.19M	$ 83.75M
Cash Flow
Free Cash Flow	$ -89.67M	$ -76.46M	$ -79.06M	$ -30.25M	$ -45.04M
Operating Cash Flow	$ -89.23M	$ -75.26M	$ -78.13M	$ -30.17M	$ -44.82M
Investing Cash Flow	$ -84.72M	$ 41.41M	$ 57.86M	$ -147.65M	$ 16.75M
Financing Cash Flow	$ 150.71M	$ 58.12M	$ 1.58M	$ 212.12M	$ 11.58M

Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

Income Statement >

KalVista Pharmaceuticals Debt to Assets

Balance Sheet >

KalVista Pharmaceuticals Cash Flow

Cash Flow >

KalVista Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing